Last reviewed · How we verify
Colloidal bismuth pectin
Colloidal bismuth pectin, marketed by the Second Affiliated Hospital, School of Medicine, Zhejiang University, holds a position in the gastrointestinal therapeutic area. The drug's key composition patent is set to expire in 2028, providing a period of exclusivity that supports its market presence. The primary risk lies in the potential for increased competition post-patent expiry, which could impact market share and revenue.
At a glance
| Generic name | Colloidal bismuth pectin |
|---|---|
| Sponsor | Second Affiliated Hospital, School of Medicine, Zhejiang University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Efficacy and Safety of Tegoprazan Dual Therapy and Furazolidone-based Bismuth Quadruple Therapy for Helicobacter Pylori Eradication: A Prospective, Multicenter, Open-label, Randomized Controlled Clinical Study (NA)
- The Impact of Helicobacter Pylori Eradication on the Vaginal Microecology Change
- Tegoprazan-Amoxicillin Dual Therapy vs. Bismuth Quadruple Therapy for H. Pylori Infection (TATH-1) (PHASE4)
- Efficacy and Safety of Keverprazan-amoxicillin Dual Therapy for Helicobacter Pylori First-line Treatment (PHASE4)
- Furazolidone Quadruple Regimen Eradicate H. Pylori Infection (PHASE1, PHASE2)
- The Efficacy and Safety of Keverprazan for Helicobacter Pylori Eradication (EARLY_PHASE1)
- Standard or Short-course Vonoprazan Non-bismuth Triple Therapy or High-dose Dual Therapy Versus Rabeprazole-bismuth Quadruple Therapy for Primary Helicobacter Pylori Eradication (PHASE4)
- Bismuth-containing Quadruple Therapy for Helicobacter Pylori First-line Treatment of Different Tetracycline Doses (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: